{"title":"子宫内暴露于 SGA 与不良神经行为结果无关","authors":"","doi":"10.1002/pu.31176","DOIUrl":null,"url":null,"abstract":"<p>Prenatal exposure to second-generation antipsychotics (SGAs) did not increase risk of adverse childhood developmental or behavioral outcomes compared with antipsychotic-unexposed children, a study examining preschool-aged children has found. This was one of the largest studies to date that examined neurobehavioral outcomes in children exposed prenatally to SGAs, the investigators reported. Study results were published online March 13, 2024, in the <i>Journal of Clinical Psychiatry</i>.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Exposure in utero to SGAs not linked to adverse neurobehavioral outcomes\",\"authors\":\"\",\"doi\":\"10.1002/pu.31176\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Prenatal exposure to second-generation antipsychotics (SGAs) did not increase risk of adverse childhood developmental or behavioral outcomes compared with antipsychotic-unexposed children, a study examining preschool-aged children has found. This was one of the largest studies to date that examined neurobehavioral outcomes in children exposed prenatally to SGAs, the investigators reported. Study results were published online March 13, 2024, in the <i>Journal of Clinical Psychiatry</i>.</p>\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31176\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Exposure in utero to SGAs not linked to adverse neurobehavioral outcomes
Prenatal exposure to second-generation antipsychotics (SGAs) did not increase risk of adverse childhood developmental or behavioral outcomes compared with antipsychotic-unexposed children, a study examining preschool-aged children has found. This was one of the largest studies to date that examined neurobehavioral outcomes in children exposed prenatally to SGAs, the investigators reported. Study results were published online March 13, 2024, in the Journal of Clinical Psychiatry.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
